Los Angeles, CA, United States of America

Robert E Reiter

This inventor holds 38 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 3 EPO patents, primarily in Cancer Antibody Development. Top assignees: University of California, Agensys, Inc., Beckman Research Institute, City of Hope. Active years: 2000-2016.

USPTO Granted Patents = 38 (Patent Applications = 11)

% Patents Active = 65.8

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 2.5

ph-index = 14

Forward Citations = 492(Granted Patents)

Company Filing History:

36 out of 15,964

University of California

Beckman Research Institute, City of Hope

5. 1 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2016

Loading Chart...

Areas of Expertise:

Prostate Stem Cell Antigen

N-cadherin

Cancer Diagnosis

Monoclonal Antibodies

Tumor Growth Inhibition

Humanized Antibodies

Mouse Models

Cancer Therapy

Angiogenesis

Metastasis

Gene Assessment

Nucleic Acids

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9527919 - High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection (2016-12-27),

2. 9470689 - N-cadherin: target for cancer diagnosis and therapy (2016-10-18),

3. 9388247 - Antibodies against cancer target block tumor growth, angiogenesis and metastatis (2016-07-12),

4. 8940871 - Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting (2015-01-27),

5. 8940298 - High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection (2015-01-27),

6. 8759006 - PSCA: prostate stem cell antigen and distinguishing androgen receptor negative prostate cancer from benign prostatic hyperplasia (2014-06-24),

7. 8703920 - Fully human antibodies against N-cadherin (2014-04-22),

8. 8663635 - N-cadherin: target for cancer diagnosis and therapy (2014-03-04),

9. 8524460 - PSCA: prostate stem cell antigen and uses thereof (2013-09-03),

10. 8404817 - Humanized anti-prostate stem cell antigen monoclonal antibody (2013-03-26),

11. 8088908 - Humanized anti-prostate stem cell antigen monoclonal antibody (2012-01-03),

12. 7595431 - Mouse models of human prostate cancer (2009-09-29),

13. 7527786 - Methods for inhibiting the growth of cancer cells expressing PSCA (2009-05-05),

14. 7485296 - PSCA: prostate stem cell antigen and uses thereof in pancreatic cancer (2009-02-03),

15. 7462691 - Mouse prostate stem cell antigen and uses thereof (2008-12-09),

Title: The Innovative Journey of Robert E. Reiter

Introduction:

Robert E. Reiter is a distinguished inventor based in Los Angeles, California. With a passion for creating groundbreaking solutions, he has made significant contributions to the field of technology through his inventive spirit and dedication.

Latest Patents:

Robert E. Reiter holds several patents in various technological domains, showcasing his versatility and ingenuity in the innovation landscape. His recent patents focus on cutting-edge advancements in artificial intelligence and renewable energy technologies.

Career Highlights:

Throughout his illustrious career, Robert E. Reiter has been at the forefront of innovation, leading pioneering projects that have reshaped industries. His work has been instrumental in revolutionizing how we interact with technology on a daily basis.

Collaborations:

Robert E. Reiter has collaborated with leading tech companies and research institutions to bring his ideas to life. His partnerships have been instrumental in driving forward innovation and pushing the boundaries of what is possible in the technological realm.

Conclusion:

In conclusion, Robert E. Reiter stands as a visionary inventor whose work continues to inspire and drive progress in the ever-evolving world of technology. His relentless pursuit of innovation and commitment to excellence make him a true trailblazer in the field of inventions.